The Coalition for Epidemic Preparedness Innovations (CEPI) and Gennova Biopharmaceuticals have announced a new funding agreement to develop vaccine candidates against unknown pathogenic threats with the particular development of saRNA vaccines that use the body s own machinery to make antigenic protein.
Read more about mRNA Covid vaccine maker Gennova lines up Rs 250-crore capex: Crisil on Business Standard. The Emcure Pharma arm has tied up with Seattle-based HDT Biotech Corp for the vaccine, on which animal trials have been completed. Phase-I and II trials likely to be completed in 2-3 months